Insider transaction details
Lori J. Braender, Chief Legal Officer at Aquestive Therapeutics (NASDAQ: AQST), sold 40,102 shares of the company's common stock on March 10, 2026. The sale occurred at prices between $4.17 and $4.32 per share and generated approximately $167,345 in proceeds.
Concurrent equity awards
A Form 4 filing with the Securities and Exchange Commission indicates that on March 9, 2026, Braender acquired 80,000 shares of Aquestive common stock valued at $0. Those shares are restricted stock that will vest in three equal annual installments. On the same date she was granted 50,000 Non-Qualified Stock Options, each with an exercise price of $4.29. The options vest in three annual installments and carry an expiration date of 2036-03-09.
Post-transaction holdings and market context
After completing the March 10 sale, Braender directly holds 442,879 shares of Aquestive Therapeutics common stock. At the time of the reported sale the stock was trading at $4.27. The share price has risen 62% over the past 12 months, yet it has fallen 34% year-to-date.
According to InvestingPro analysis cited in the filing, the stock appears overvalued at current prices, with a calculated Fair Value of $3.28.
Financial results and strategic milestones
Aquestive reported fourth-quarter 2025 results showing a larger-than-expected loss. The company posted a net loss of $0.26 per share versus analyst expectations for a $0.13 per-share loss. Revenue for the quarter totaled $13.0 million, slightly under the $13.34 million that had been anticipated.
Separately, Citizens has reiterated a Market Outperform rating on Aquestive and kept a $10.00 price target. The firm referenced a clear path to re-submission for the company’s Anaphylm NDA and noted that an FDA meeting is scheduled to clarify remaining steps. Aquestive has reiterated its plan to re-submit the application in the third quarter of 2026.
Research and access
For investors seeking more granular analysis of AQST’s financial position and executive activity, a Pro Research Report covering Aquestive and over 1,400 U.S. equities is available.
Note on reported figures
All transactional details above are reported as presented in the referenced SEC filing and corporate disclosures.